# SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

> **NCT01329289** · PHASE2 · WITHDRAWN · sponsor: **University of Pittsburgh**

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma

## Interventions

- **DRUG:** SOM230
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01329289
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Clinical trial being transferred to Columbia University with the Investigator.
- **Last updated:** 2016-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01329289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01329289, "SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01329289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*